The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Chris Howerton - Jefferies Group LLC - Analyst
: Yes, sure. So I have a question. I can certainly ask, but if there's any from the audience, we would love to entertain those too. So maybe in the
meantime, I'll just start off by asking about -- obviously, the Phase III trial just started. And I know you showed this schematic up there, but maybe
you could describe it relative to other pivotal trials in this space.
And you know how investors are, we're going to try and figure out timelines and all those other kinds of things, so if you could help us relate it to
those other studies, I guess.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JUNE 07, 2023 / 6:00PM, SYBX.OQ - Synlogic Inc at Jefferies Healthcare Conference
Question: Chris Howerton - Jefferies Group LLC - Analyst
: Okay. Well, very good. So then I guess -- you touched on it briefly, but obviously, the safety has been excellent of the drug in the modality. But this
would be a relatively new modality, so is there anything like a database requirement that you're aware of or anything like that?
Question: Chris Howerton - Jefferies Group LLC - Analyst
: Okay. Yes, go ahead.
Unidentified Participant
(inaudible - microphone inaccessible)
Question: Chris Howerton - Jefferies Group LLC - Analyst
: Okay. Well, thanks, everybody, for joining us. And thank you, Aoife, for presenting.
|
